Pfizer Inc
FDA vaccine head will step down in April after string of controversial decisions
The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]
Read More
AI disruption didn’t show up in Salesforce results. But the fears are hard to shake
Salesforce on Wednesday evening delivered better-than-expected 2026 fourth-quarter results as its Agentforce artificial intelligence platform became increasingly embedded across the business. However, the stock dropped in after-hours trading as investors remained anxious about the potential of AI disrupting traditional enterprise software companies. Revenue in the quarter ended Jan. 31 rose 12% year over year to […]
Read More
These 4 charts show the scale of Novo Nordisk’s woes
Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most valuable company. But its troubles are stacking up and today the stock trades at just a quarter of what it did at its peak less than two years ago. Pricing pressure, fierce competition, and pipeline setbacks have […]
Read More
Russia’s war on Ukraine puts women off having children — and that could spell economic disaster
A woman carries a baby as she reacts after evacuating from Russian troop-occupied Kupiansk town in a bus convoy, amid Russia’s attack on Ukraine, on the outskirts of Kharkiv, Ukraine May 30, 2022. Picture taken May 30, 2022. Ivan Alvarado | Reuters Four years of war between Russia and Ukraine are beginning to take their […]
Read More
Jim Cramer’s top 10 things to watch in the stock market Friday
My top 10 things to watch Friday, Feb. 20 1. Blue Owl Capital’s loan sales, part of a plan to return capital to investors, has observers bringing out “canary in the coal mine” warnings again. While many private credit loans seem mismarked, this situation doesn’t appear tragic in nature. 2. Stock futures were lower after […]
Read More
Walmart earnings, Fed meeting minutes, Zuckerberg’s testimony and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Thursday. My spin class soundtrack of mainly Kesha’s music last night was more evidence that the 2016 aesthetic is back. Stock futures are lower this morning. The three major indexes are coming off a winning session. Here are five key things […]
Read More
FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal
A researcher works in the lab at the Moderna headquarters in Cambridge, Massachusetts, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna said on Wednesday the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing the agency’s earlier decision to refuse to accept the application in a move […]
Read More
FDA chief Marty Makary says ‘everything should be over the counter’ unless drug is unsafe or addictive
Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over the counter” unless a drug is unsafe, addictive or requires monitoring – doubling down on a push that some in the pharmaceutical industry have questioned. In an interview Wednesday in Washington, D.C., Makary said the FDA aims to make […]
Read More
Prices, pipelines and patent cliffs: Inside pharma’s big reset
This earnings season, Europe’s biggest pharma companies posted results ranging from 7% beats to 3% misses — but no one really cared. Instead, drugmakers looked ahead, with 2026 shaping up to be a defining year following a dramatic 2025, and one where the impact from last year’s developments is set to crystallize. “2025 was about […]
Read More
Stocks making the biggest moves midday: Novo Nordisk, Palantir, AES, Rocket and more
Check out the companies making headlines before the bell: Novo Nordisk — The maker of obesity drug Wegovy’s U.S. stock fell about 13% after unexpectedly warning that fiscal 2026 sales will be hurt by lower drug prices in the U.S. even as it anticipates more patients will use its popular GLP-1 drug. Novo Nordisk said […]
Read More